Fig. 5: H10ssF vaccination elicited binding antibodies against heterologous group 2 influenza HAs. | npj Vaccines

Fig. 5: H10ssF vaccination elicited binding antibodies against heterologous group 2 influenza HAs.

From: Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Fig. 5

Binding antibodies were assayed using the H7 stabilized stem (H7ss, a, b) or full-length (H7FL, c, d) antigens, or the H3ss antigen (e, f) by ECLIA. The GM of the 60 mcg recipients’ binding antibodies in AU/mL (a, c, e) or fold change (b, d, f) are shown with 95% CI in black, with individual participants’ AU/mL in red or blue based on their age group. In (b), (d), (f), the dashed line represents no change over baseline. Brackets indicate two time points that are significantly different from each other, with the p value noted above the line. When the significance between a timepoint and baseline is p < 0.001, this is noted by a symbol above the later timepoint.

Back to article page